{"id":3972,"date":"2026-03-06T14:34:45","date_gmt":"2026-03-06T06:34:45","guid":{"rendered":"https:\/\/web.csh.org.tw\/web\/222040-2\/?page_id=3972"},"modified":"2026-03-06T14:34:45","modified_gmt":"2026-03-06T06:34:45","slug":"%e5%aa%92%e5%90%88%e8%a8%88%e7%95%ab%e4%b8%bb%e6%8c%81%e4%ba%ba-%e6%84%9f%e6%9f%93%e7%a7%91-%e6%9d%8e%e8%82%b2%e9%9c%96%e4%b8%bb%e6%b2%bb%e9%86%ab%e5%b8%ab","status":"publish","type":"page","link":"https:\/\/web.csh.org.tw\/web\/222040-2\/?page_id=3972","title":{"rendered":"\u5a92\u5408\u8a08\u756b\u4e3b\u6301\u4eba\/\u611f\u67d3\u79d1\/\u674e\u80b2\u9716\u4e3b\u6cbb\u91ab\u5e2b"},"content":{"rendered":"\n
\n
\n
\"\"<\/figure><\/div><\/div>\n\n\n\n
\n
\u73fe\u8077\uff1a<\/strong><\/td>– \u4e2d\u5c71\u91ab\u5b78\u5927\u5b78\u9644\u8a2d\u91ab\u9662\u611f\u67d3\u79d1\u4e3b\u6cbb\u91ab\u5e2b
– \u4e2d\u5c71\u91ab\u5b78\u5927\u5b78\u91ab\u5b78\u7cfb\u52a9\u7406\u6559\u6388<\/td><\/tr>
\u5c08\u9577\uff1a<\/strong><\/td>\u5e38\u898b\u50b3\u67d3\u75c5\u7684\u8a3a\u65b7\u8207\u6cbb\u7642\uff0c\u4f8b\u5982\uff1a\u4eba\u9ad4\u5404\u90e8\u56e0\u7d30\u83cc\u3001\u75c5\u6bd2\u6216\u5176\u5b83\u75c5\u539f\u9ad4\u5f15\u8d77\u4e4b\u611f\u67d3 \u3001\u5404\u7a2e\u539f\u56e0\u5f15\u8d77\u4e4b\u767c\u71d2\u53ca\u4e0d\u660e\u539f\u56e0\u4e4b\u767c\u71d2\u3001\u611f\u5192\u3001\u6241\u6843\u817a\u708e\u3001\u6c23\u7ba1\u708e\u3001\u80ba\u708e\u6027\u75c5\u3001\u6885\u6bd2\u3001\u6dcb\u75c5\u3001\u5c3f\u9053\u708e\u3001\u8180\u80f1\u708e\u3001\u814e\u76c2\u708e\u3001\u9aa8\u9ad3\u708e\u3001\u8702\u7aa9\u6027\u7d44\u7e54\u708e\u3001\u8166\u819c\u708e\u3001\u8166\u708e\u3001\u7d50\u6838\u75c5\u3001\u80ba\u7d50\u6838\u53ca\u611b\u6ecb\u75c5\u7b49<\/td><\/tr>
\u904e\u53bb\u4e94\u5e74\u5167\u57f7\u884c\u81e8\u5e8a\u8a66\u9a57\u6848\u4ef6\u6578\uff1a<\/strong><\/td>1 \u4ef6<\/td><\/tr>
\u8fd1\u4e94\u5e74\u8ad6\u6587\u8457\u4f5c\uff1a<\/strong><\/td>\u300a2025\u300b\u674e\u80b2\u9716\u3001\u859b\u535a\u4ec1
Expert Review of Anti-Infective Therapy 2025 Nov;23(11):1095-1117
An update on antimicrobial selection and duration for intra-abdominal infections
\u300a2025\u300b\u674e\u80b2\u9716\u3001\u90ed\u66f8\u8fb0\u3001\u694a\u96c5\u980c
International journal of antimicrobial agents 2025 Sep;66(3):107550
In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022
\u300a2025\u300b\u674e\u80b2\u9716\u3001\u694a\u96c5\u980c\u3001\u90ed\u66f8\u8fb0
Journal of Microbiology, Immunology and Infection 2025 Apr;58(2):219-225
Antimicrobial resistance among imipenem-non-susceptible Escherichia coli and Klebsiella pneumoniae isolates, with an emphasis on novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and tetracycline derivatives: The Taiwan surveillance of antimicrobial resistance program, 2020-2022
\u300a2024\u300b\u694a\u96c5\u980c\u3001\u674e\u80b2\u9716\u3001\u90ed\u66f8\u8fb0
International Journal of Antimicrobial Agents 2024 Dec;64(6):107378
Acquired blaCfxA-3 carried by a conjugative transposon or duplicated intrinsic blaCME-3 mediates cefiderocol resistance in Elizabethkingia anophelis clinical isolates
\u300a2024\u300b\u8cf4\u6021\u742a\u3001\u674e\u80b2\u9716(\u901a\u8a0a\u4f5c\u8005)
International Journal of Antimicrobial Agents 2024 Nov;64(5):107342
Conversion of blaKPC-2 to blaKPC-33 leads to worldwide emergence of ceftazidime-avibactam resistance in Klebsiella pneumoniae
\u300a2024\u300b\u674e\u80b2\u9716\u3001\u859b\u535a\u4ec1
Journal of Microbiology, Immunology and Infection 2024 Aug;57(4):523-532
Burden of respiratory syncytial virus in older adults in Taiwan: An expert perspective on knowledge gaps
\u300a2024\u300b\u674e\u80b2\u9716\u3001\u859b\u535a\u4ec1
Journal of Antimicrobial Chemotherapy 2024 Jul 1;79(7):1581-1589.
Global epidemiology and antimicrobial resistance of Enterobacterales harbouring genes encoding OXA-48-like carbapenemases: insights from the results of the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme 2018-2021
\u300a2024\u300b\u8cf4\u6021\u742a\u3001\u674e\u80b2\u9716(\u901a\u8a0a\u4f5c\u8005)
International Journal of Antimicrobial Agents 2024 May 23;64(2):107213.
Emergence of ceftazidime-avibactam resistance through in-vivo blaKPC-2 to blaKPC-33 conversion during treatment of ST11 Klebsiella pneumoniae associated infections
\u300a2024\u300b\u674e\u80b2\u9716\u3001\u859b\u535a\u4ec1
Journal of Microbiology Immunology and Infection 2024 Jun;57(3):446-456
Epidemiology and antimicrobial susceptibility profiles of Enterobacterales causing bloodstream infections before and during COVID-19 pandemic: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2018-2021
\u300a2023\u300b\u674e\u80b2\u9716\u3001\u859b\u535a\u4ec1
Current Opinion in Infectious Diseases 2023 Dec 1;36(6):481-494.
Emerging infections in vulnerable hosts: Stenotrophomonas maltophilia and Elizabethkingia anophelis
\u300a2023\u300b\u674e\u80b2\u9716\u3001Po-Ren Hsueh
International journal of antimicrobial agents 2023 Aug;62(2):106878
In vitro susceptibilities of Stenotrophomonas maltophilia isolates to antimicrobial agents commonly used for related infections: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2004-2020
\u300a2023\u300b\u674e\u80b2\u9716\u3001Po-Ren Hsueh
International journal of antimicrobial agents 2023 Aug;62(2):106867
In vitro activities of ceftazidime\u2013avibactam, ceftolozane\u2013tazobactam, meropenem\u2013vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012\u20132021
\u300a2023\u300b\u674e\u80b2\u9716\u3001Po-Ren Hsueh
Journal of infection 2023 Jul;87(1):e1-e4
Poor in vitro activity of ceftazidime\/avibactam, ceftolozane\/tazobactam, and meropenem\/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021<\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

\u73fe\u8077\uff1a – \u4e2d\u5c71\u91ab\u5b78\u5927\u5b78\u9644\u8a2d\u91ab\u9662\u611f\u67d3\u79d1\u4e3b\u6cbb\u91ab\u5e2b– \u4e2d\u5c71\u91ab\u5b78\u5927\u5b78\u91ab\u5b78\u7cfb\u52a9\u7406\u6559\u6388 \u5c08\u9577\uff1a […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3972","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/web.csh.org.tw\/web\/222040-2\/index.php?rest_route=\/wp\/v2\/pages\/3972"}],"collection":[{"href":"https:\/\/web.csh.org.tw\/web\/222040-2\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/web.csh.org.tw\/web\/222040-2\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/web.csh.org.tw\/web\/222040-2\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/web.csh.org.tw\/web\/222040-2\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3972"}],"version-history":[{"count":6,"href":"https:\/\/web.csh.org.tw\/web\/222040-2\/index.php?rest_route=\/wp\/v2\/pages\/3972\/revisions"}],"predecessor-version":[{"id":4146,"href":"https:\/\/web.csh.org.tw\/web\/222040-2\/index.php?rest_route=\/wp\/v2\/pages\/3972\/revisions\/4146"}],"wp:attachment":[{"href":"https:\/\/web.csh.org.tw\/web\/222040-2\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}